TriSalus Life Sciences reported second-quarter revenue of $11.4 million, a 1.7% increase from $11.2 million a year earlier, and reiterated its full-year 2026 revenue forecast of $54 million to $57 million. The company more than doubled its commercial footprint in the first half of the year, with all new sales representatives in place by April. A new CMS G-code could extend reimbursement for the TriNav pressure-enabled drug delivery system into physician office-based labs, potentially supporting growth in liver, uterine, prostate, and genicular artery embolization procedures. Gross margin improved to 86.8% from 83.9%, but higher sales and marketing costs from the expanded sales force widened the adjusted EBITDA loss to approximately $7.1 million from $5.3 million. TriSalus ended the quarter with about $46.3 million in cash and expects sequential revenue improvement in the second half of 2026.
TriSalus Life Sciences Inc.Revenue growth and expanded commercial footprint indicate increased adoption of TriNav system.
